Ritonavir exhibits limited efficacy as a single agent in treating aggressive mantle cell lymphoma
暂无分享,去创建一个
[1] D. Weisenburger,et al. Novel therapy for therapy‐resistant mantle cell lymphoma: Multipronged approach with targeting of hedgehog signaling , 2012, International journal of cancer.
[2] S. Carroll,et al. Combination antiretroviral therapy as treatment for human immunodeficiency virus‐associated mucosa‐associated lymphoid tissue type lymphoma of the nasopharynx , 2011, Internal medicine journal.
[3] A. Srirangam,et al. The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of Survivin , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] P. Iversen,et al. Antisense Inhibition of Survivin Expression as a Cancer Therapeutic , 2011, Molecular Cancer Therapeutics.
[5] C. Geisler. Front-line treatment of mantle cell lymphoma , 2010, Haematologica.
[6] I. Pastan,et al. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl‐2 expression , 2010, British journal of haematology.
[7] Yasodha Natkunam,et al. Characterization of D-Cyclin Proteins in Hematolymphoid Neoplasms: Lack of Specificity of Cyclins D2 and D3 Expression in Lymphoma Subtypes , 2009, Modern Pathology.
[8] W. Klapper,et al. Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR , 2009, Haematologica.
[9] B. Kahl. Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents , 2009, Current hematologic malignancy reports.
[10] M. Leandro,et al. Rituximab in non‐haematological disorders of adults and its mode of action , 2009, British journal of haematology.
[11] J. Schellens,et al. Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors , 2009, Clinical Cancer Research.
[12] Kenji Sugimoto,et al. Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells , 2009, Drug Metabolism and Disposition.
[13] N. Mori,et al. An HIV protease inhibitor, ritonavir targets the nuclear factor‐kappaB and inhibits the tumor growth and infiltration of EBV‐positive lymphoblastoid B cells , 2009, International journal of cancer.
[14] W. Hiddemann,et al. Current treatment standards and emerging strategies in mantle cell lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.
[15] A. Rosenwald,et al. Signal transduction pathways of mantle cell lymphoma: A phosphoproteome‐based study , 2008, Proteomics.
[16] P. Dennis,et al. Repositioning HIV protease inhibitors as cancer therapeutics , 2008, Current opinion in HIV and AIDS.
[17] M. Westergaard,et al. SPC3042: a proapoptotic survivin inhibitor , 2008, Molecular Cancer Therapeutics.
[18] M. Raffeld,et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2 , 2008, Leukemia.
[19] H. Ovaa,et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis , 2008, Molecular Cancer Therapeutics.
[20] T. Greiner,et al. Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma , 2008, Molecular Cancer Therapeutics.
[21] C. Doglioni,et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. , 2008, Blood.
[22] Benjamin Frey,et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. , 2008, International journal of radiation oncology, biology, physics.
[23] Michael L. Wang,et al. Immunotherapy in mantle cell lymphoma: Anti‐CD20‐based therapy and beyond , 2008, American journal of hematology.
[24] E. Campo,et al. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.
[25] J. LoPiccolo,et al. Targeting Akt in cancer therapy. , 2007, Anti-cancer drugs.
[26] D. Weisenburger,et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. , 2006, Blood.
[27] D. Iliopoulos,et al. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential , 2006, Oncogene.
[28] Christie M. Orschell,et al. Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer , 2006, Clinical Cancer Research.
[29] F. Cavalli,et al. Update on the molecular biology of mantle cell lymphoma , 2006, Hematological oncology.
[30] Mamoru Ito,et al. leukemia cells by an HIV protease inhibitor, ritonavir , 2005 .
[31] Nerea Martínez,et al. Expression of the NF‐κB targets BCL2 and BIRC5/Survivin characterizes small B‐cell and aggressive B‐cell lymphomas, respectively , 2005, The Journal of pathology.
[32] Y. Ohtsuki,et al. HIV-1 Protease Inhibitor, Ritonavir , 2004, Cancer Research.
[33] S. Ansell,et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma , 2004, Leukemia.
[34] F. Bosch,et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. , 2004, The American journal of pathology.
[35] R. Zeldin,et al. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.
[36] C. Galanos,et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. , 2002, Cancer research.
[37] Jie Chen,et al. Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.
[38] H. J. Kim,et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. , 2001, Biochemistry.
[39] Hui Zhang,et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.